Transcripta Bio Named to the TIME100 Most Influential Companies of 2024
Leading Biotech Company Recognized for Speeding Drug Discovery.
Palo Alto, Calif., May 30, 2024 – Transcripta Bio, a platform drug development biotechnology company that is revolutionizing discovering and developing medicines at unprecedented speed, scale, and capital efficiency, has been included in the fourth-annual TIME100 Most Influential Companies list. The prestigious list spotlights companies around the world that are making an extraordinary impact and recognizes Transcripta Bio’s significant achievements in speeding drug discovery.
“We are honored to be included in the TIME100 Most Influential Companies list and recognized for our groundbreaking advancements in drug discovery,” said Chris Moxham, co-founder, CEO, and Chief Scientific Officer, Transcripta Bio. “‘Charting a faster path in drug discovery to create better lives for people around the world’ is our mission and having our strong progress towards achieving this acknowledged today is a milestone moment. I want to thank our world-class team of scientists and technology leaders in AI and ML for their outstanding work and dedication to helping humanity.”
The TIME100 Most Influential Companies list acknowledges Transcripta Bio for “dramatically reducing the time and money it takes to discover drugs —not just for rare diseases, but for any drug that treats disease by changing gene expression. Transcripta Bio’s Drug-Gene Atlas database shows how small molecules affect gene expression, allowing it to identify new uses for already-approved pharmaceuticals and, with the help of AI, novel candidates. In less than two years, Transcripta moved five FDA-approved drugs into single-patient studies for new indications, which otherwise might have taken five to eight years.”
Transcripta Bio is dedicated to high certainty drug discovery. By focusing on diseases where the causality is unequivocally established by human genetics, Transcripta Bio leverages the universe of small molecules that has consistently led to successful drugs. Transcripta Bio’s Drug-Gene Atlas maps molecular structure and drug action to the whole cell transcriptome, revealing therapeutic candidates that rebalance gene expression to treat disease. The proprietary artificial intelligence modeling suite, Conductor AI, utilizes the Drug-Gene Atlas to discover and predict the effects of new drugs at transcriptome scale. By building cutting-edge technology and forging strategic partnerships, Transcripta Bio is dramatically accelerating the global drug discovery process.
To assemble the list, TIME solicited nominations across sectors, and polled its global network of contributors and correspondents, as well as outside experts. TIME editors evaluated each on key factors, including impact, innovation, ambition, and success. The result is a diverse group of 100 businesses helping chart an essential path forward. Read the full list here: time.com/100companies.
About Transcripta Bio
Transcripta Bio is dedicated to high-certainty drug discovery, revolutionizing the process of discovering and developing medicines at unprecedented speed, scale, and capital efficiency.
With data from hundreds of millions of experiments, we have mapped the effects of thousands of compounds on gene expression to discover new therapies. Using technology at scale, we discover new therapies for multiple diseases simultaneously. Transcripta is headquartered in Palo Alto, Calif. For more information, please visit www.transcriptabio.com/.
Contact
